The goal of the TEAM Study is to help us understand how extended-release formulation of mixed amphetamine salts (MAS) can be used to treat Attention Deficit/ Hyperactivity Disorder (ADHD) in children and adolescents with also diagnosed with Autism Spectrum Disorder (ASD). We also want to find out if taking MAS has any effect on the brains of children and adolescents with ADHD and ASD. This study is conducted by researchers at the Massachusetts Institute of Technology (MIT) and Massachusetts General Hospital (MGH).
If your child does not have a diagnosis of ADHD or ASD, they will complete eligibility screening with MGH. If eligible, they will be invited to baseline and endpoint MRI scan visits at MIT. During the MRI Scan visits, they will complete a series of tasks to measure inattention, impulsivity, reward sensitivity, decision-making, and working memory. Children without ADHD and ASD will not receive any study medication/placebo.
Participation: Your child may eligible if they:
– Is between 8-18 years old.
– Does NOT have a diagnosis of ADHD or Autism Spectrum Disorder.
Participation Requires
– Eligibility screening with Massachusetts General Hospital
– 2 scanning visits at Massachusetts Institute of Technology (separated by 4 weeks)
Compensation
You will be compensated up to $180, receive a picture of your brain and contribute to scientific knowledge.
Currently enrolling children WITHOUT a diagnosis of Autism or ADHD.
